In Mice, a Rebooted Immunotherapy Safely Links T Cells to their Tumor Targets (4 of 5) (VIDEO)

American Association for the Advancement of Science (AAAS)

Caption

The new therapy forms a synapse and cross-links tumor cells (blue) and T cells (green) via the molecules CD19-4-1BBL (purple) and CD20-TCB. This material relates to a paper that appeared in the Jun. 19, 2019, issue of Science Translational Medicine, published by AAAS. The paper, by C. Claus at Roche Innovation Center Zurich in Schlieren, Switzerland; and colleagues was titled, "Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy."

Credit

[Credit: Dr. Mario Perro, Stanford Chen and Sara Colombetti at Roche Innovation Center Zurich]

Usage Restrictions

Please cite the owner of the material when publishing. This material may be freely used by reporters as part of news coverage, with proper attribution. Non-reporters must contact <i>Science</i> for permission.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.